WHAT IS CLAIMED IS:

1. A compound of the formula



wherein:

n is an integer selected from 0, 1, and 2;

A is R^5O-, monosubstituted amino, or disubstituted amino;

A′ is $R^{5'}O$-, monosubstituted amino, or disubstituted amino;

R^1 is hydrogen or C_1-C_6 alkyl;

R^2 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, halo, haloalkyl, cyano, formyl, alkylcarbonyl, alkoxycarbonyl, or a substituent selected from the group consisting of $-CO_2R^8$, $-CONR^8R^{8'}$, and $-NR^8(COR^9)$;

R^3 is a structure selected from the group consisting of



;

R^4 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_8 cycloalkyl, C_3-C_9 cycloalkenyl, C_1-C_3 alkylcarbonyl, optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), optionally substituted aryl(C_2-C_4 alkenyl), or optionally substituted aryl(C_2-C_4 alkynyl);

R^5 and $R^{5'}$ are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, (C_1-C_4 alkoxy)-(C_1-C_4 alkyl), optionally substituted aryl(C_1-C_4 alkyl), Y-, Y-(C_1-C_4 alkyl), Y′-, Y′-(C_1-C_4 alkyl), R^6R^7N-(C_2-C_4 alkyl), and $R^{6'}R^{7'}N$-(C_2-C_4 alkyl);

where Y and Y′ are each independently selected from the group consisting of tetrahydrofuryl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, and quinuclidinyl; where said morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, or quinuclidinyl is optionally N-substituted with C_1-C_4 alkyl or optionally substituted aryl(C_1-C_4 alkyl);

R^6 is hydrogen or C_1-C_6 alkyl;

R^7 is C_1-C_6 alkyl, C_3-C_8 cycloalkyl, optionally substituted aryl, or optionally substituted aryl(C_1-C_4 alkyl); or

R^6 and R^7 are taken together with the attached nitrogen atom to form an heterocycle selected from the group consisting of pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and homopiperazinyl; where said piperazinyl or homopiperazinyl is optionally N-substitued with R^{13};

$R^{6'}$ is hydrogen or C_1-C_6 alkyl;

$R^{7'}$ is C_1-C_6 alkyl, C_3-C_8 cycloalkyl, optionally substituted aryl, or optionally substituted aryl(C_1-C_4 alkyl); or

$R^{6'}$ and $R^{7'}$ are taken together with the attached nitrogen atom to form an heterocycle selected from the group consisting of pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and homopiperazinyl; where said piperazinyl or homopiperazinyl is optionally N-substituted with $R^{13'}$;

R^8 and $R^{8'}$ are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, optionally substituted aryl, and optionally substituted aryl(C_1-C_4 alkyl); or

R^8 and $R^{8'}$ are taken together with the attached nitrogen atom to form an heterocycle selected from the group consisting of optionally substituted pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and homopiperazinyl;

R^9 is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, (C_1-C_4 alkoxy)-(C_1-C_4 alkyl), optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(C_1-C_4 alkyl), and $R^8R^{8'}N$-(C_1-C_4 alkyl);

R^{10} and R^{11} are each independently selected from the group consisting of hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_8 cycloalkyl, C_1-C_4 alkoxycarbonyl, C_1-C_5 alkylcarbonyloxy, optionally substituted aryl, optionally

substituted aryl(C_1-C_4 alkyl), optionally substituted aryl(C_1-C_4 alkyloxy), optionally substituted aryl(C_1-C_4 alkylcarbonyloxy), diphenylmethoxy, and triphenylmethoxy;

R^{12}, R^{13}, and $R^{13'}$ are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_1-C_4 alkoxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted aryl(C_1-C_4 alkyl), and optionally substituted aryloyl; and

hydrates, solvates, and pharmaceutically acceptable salts thereof.

2. The compound of claim 1, wherein A is acyclic disubstituted amino.

3. The compound of claim 1, wherein A is cyclic disubstituted amino.

4. The compound of claim 1, wherein A is monosubstituted amino of the formula XNH-, where X is selected from the group consisting of C_1-C_6 alkyl, C_3-C_8 cycloalkyl, (C_1-C_4 alkoxy)-(C_1-C_4 alkyl), optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), optionally substituted aryl(C_3-C_7 cycloalkyl), optionally substituted indan-1-yl, optionally substituted indan-2-yl, optionally substituted 1,2,3,4-tetrahydronaphth-1-yl, optionally substituted 1,2,3,4-tetrahydronaphth-2-yl, Y, Y-(C_1-C_4 alkyl), R^6R^7N-, and R^6R^7N-(C_2-C_4 alkyl).

5. The compound of claim 1, wherein A is disubstituted amino of the formula $R^{14}XN$-; where R^{14} is selected from the group consisting of hydroxy, C_1-C_6 alkyl, C_1-C_4 alkoxycarbonyl, and benzyl; and where X is selected from the group consisting of C_1-C_6 alkyl, C_3-C_8 cycloalkyl, (C_1-C_4 alkoxy)-(C_1-C_4 alkyl), optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), optionally substituted aryl(C_3-C_7 cycloalkyl), optionally substituted indan-1-yl, optionally substituted indan-2-yl, optionally substituted 1,2,3,4-tetrahydronaphth-1-yl, optionally substituted 1,2,3,4-tetrahydronaphth-2-yl, Y, Y-(C_1-C_4 alkyl), R^6R^7N-, and R^6R^7N-(C_2-C_4 alkyl).

6. The compound of claim 1, wherein A is disubstituted amino of the formula $R^{14}XN$-, where R^{14} and X are taken together with the attached nitrogen atom to form an optionally substituted heterocycle selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, pyrrolidinonyl, piperidinonyl, 2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl, and 1,2,3,4-tetrahydroisoquinolin-2-yl.

7. The compound of claim 6, wherein the optionally substituted heterocycle is substituted with a substituent selected from the group consisting of

optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_8 cycloalkyl, C_1-C_4 alkoxycarbonyl, C_1-C_5 alkylcarbonyloxy, optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), optionally substituted aryl(C_1-C_4 alkyloxy), optionally substituted aryl(C_1-C_4 alkylcarbonyloxy), R^6R^7N-, and R^6R^7N-(C_1-C_4 alkyl).

8. The compound of claim 6, wherein R^{14} and X are taken together with the attached nitrogen atom to form piperidinyl optionally substituted at the 4-position with hydroxy, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, (C_1-C_4 alkoxy)carbonyl, (hydroxy(C_2-C_4 alkyloxy))-(C_2-C_4 alkyl), R^6R^7N-, R^6R^7N-(C_1-C_4 alkyl), diphenylmethyl, optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), or piperidin-1-yl(C_1-C_4 alkyl).

9. The compound of claim 6, wherein R^{14} and X are taken together with the attached nitrogen atom to form piperazinyl optionally substituted at the 4-position with C_1-C_6 alkyl, C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), α-methylbenzyl, N-(C_1-C_5 alkyl) acetamid-2-yl, N-(C_3-C_8 cycloalkyl) acetamid-2-yl, R^6R^7N-, or (C_1-C_4 alkoxy)carbonyl.

10. The compound of claim 6, wherein R^{14} and X are taken together with the attached nitrogen atom to form homopiperazinyl optionally substituted in the 4-position with C_1-C_4 alkyl, aryl, or aryl(C_1-C_4 alkyl).

11. The compound of claim 1, wherein A′ is acyclic disubstituted amino.

12. The compound of claim 1, wherein A′ is cyclic disubstituted amino.

13. The compound of claim 1, wherein A′ is monosubstituted amino of the formula X′NH-, where X′ is selected from the group consisting of C_1-C_6 alkyl, C_3-C_8 cycloalkyl, (C_1-C_4 alkoxy)-(C_1-C_4 alkyl), optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), optionally substituted aryl(C_3-C_7 cycloalkyl), optionally substituted indan-1-yl, optionally substituted indan-2-yl, optionally substituted 1,2,3,4-tetrahydronaphth-1-yl, optionally substituted 1,2,3,4-tetrahydronaphth-2-yl, Y′, Y′-(C_1-C_4 alkyl), $R^{6'}R^{7'}N$-, and $R^{6'}R^{7'}N$-(C_2-C_4 alkyl).

14. The compound of claim 1, wherein A′ is disubstituted amino of the formula $R^{14'}X'N$-; where $R^{14'}$ is selected from the group consisting of hydroxy, C_1-C_6 alkyl, C_1-C_4 alkoxycarbonyl, and benzyl; and where X′ is selected from the group

consisting of C_1-C_6 alkyl, C_3-C_8 cycloalkyl, (C_1-C_4 alkoxy)-(C_1-C_4 alkyl), optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), optionally substituted aryl(C_3-C_7 cycloalkyl), optionally substituted indan-1-yl, optionally substituted indan-2-yl, optionally substituted 1,2,3,4-tetrahydronaphth-1-yl, optionally substituted 1,2,3,4-tetrahydronaphth-2-yl, Y′, Y′-(C_1-C_4 alkyl), $R^{6'}R^{7'}N$-, and $R^{6'}R^{7'}N$-(C_2-C_4 alkyl).

15. The compound of claim 1, wherein A′ is disubstituted amino of the formula $R^{14'}X'N$-, where $R^{14'}$ and X′ are taken together with the attached nitrogen atom to form an optionally substituted heterocycle selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, pyrrolidinonyl, piperidinonyl, 2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl, and 1,2,3,4-tetrahydroisoquinolin-2-yl.

16. The compound of claim 15, wherein the optionally substituted heterocycle is substituted with a substituent selected from the group consisting of optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_8 cycloalkyl, C_1-C_4 alkoxycarbonyl, C_1-C_5 alkylcarbonyloxy, optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), optionally substituted aryl(C_1-C_4 alkyloxy), optionally substituted aryl(C_1-C_4 alkylcarbonyloxy), $R^{6'}R^{7'}N$-, and $R^{6'}R^{7'}N$-(C_1-C_4 alkyl).

17. The compound of claim 15, wherein $R^{14'}$ and X′ are taken together with the attached nitrogen atom to form piperidinyl optionally substituted at the 4-position with hydroxy, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_1-C_4 alkoxy, (C_1-C_4 alkoxy)carbonyl, (hydroxy(C_2-C_4 alkyloxy))-(C_2-C_4 alkyl), $R^{6'}R^{7'}N$-, $R^{6'}R^{7'}N$-(C_1-C_4 alkyl), diphenylmethyl, optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), or piperidin-1-yl(C_1-C_4 alkyl).

18. The compound of claim 15, wherein $R^{14'}$ and X′ are taken together with the attached nitrogen atom to form piperazinyl optionally substituted at the 4-position with C_1-C_6 alkyl, C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted aryl(C_1-C_4 alkyl), α-methylbenzyl, N-(C_1-C_5 alkyl) acetamid-2-yl, N-(C_3-C_8 cycloalkyl) acetamid-2-yl, $R^{6'}R^{7'}N$-, or (C_1-C_4 alkoxy)carbonyl.

19. The compound of claim 15, wherein $R^{14'}$ and X′ are taken together with the attached nitrogen atom to form homopiperazinyl optionally substituted in the 4-position with C_1-C_4 alkyl, aryl, or aryl(C_1-C_4 alkyl).

20. The compound of any of claims 1-19, wherein R^3 is a structure selected from the group consisting of



21. The compound of any of claims 1-19, wherein R^3 is



22. The compound of any of claims 1-19, wherein R^4 is optionally substituted aryl(C_1-C_4 alkyl), optionally substituted aryl(C_2-C_4 alkenyl), or optionally substituted aryl(C_2-C_4 alkynyl).

23. The compound of any of claims 1-19, wherein R^4 is optionally substituted aryl(C_2-C_4 alkenyl).

24. The compound of any of claims 1-24, wherein R^{10} is optionally substituted phenyl.

25. The compound of any of claims 1-25, wherein A is monosubstituted amino of the formula XNH-, where X is optionally substituted aryl(C_1-C_4 alkyl).

26. The compound of any of claims 1-26, wherein A′ is disubstituted amino of the formula $R^{14'}X'N$-, where $R^{14'}$ and X′ are taken together with the attached nitrogen atom to form an optionally substituted heterocycle selected from the group consisting of optionally substituted piperidinyl and optionally substituted piperazinyl.

27. A pharmaceutical composition comprising the compound of any of the preceding claims, and a pharmaceutically acceptable carrier, diluent, or excipient.

28. A process for preparing a compound of the formula:



where Ar^1, Ar^2, R^1, R^2, R^4, n, A, and A′ are as defined in claim 1, comprising the step of reacting a compound of the formula:



with a compound of the formula:



29. A method for treating a disease state responsive to antagonism of a vasopressin V_{1a} receptor in a mammal in need of such treatment, comprising the step of administering to the mammal a pharmaceutically effective amount of the compound of any of claims 1-26 or a pharmaceutical composition of claim 27.